

Investigator initiated clinical trials (IICTs): a systematic search in registries comparing Czech Republic and Portugal in terms of funding policies and scientific outcomes

Catarina Madeira

Universidade Nova de Lisboa Faculdade de Ciencias e Tecnologia <https://orcid.org/0000-0002-5053-9421>

Lenka Hořavová

Masaryk University

Francisco dos Santos

StemLab

Joana Bataca

Universidade Nova de Lisboa Faculdade de Ciencias Medicas

Katerina Nebeska

Masaryk University

Lenka Souckova

Masaryk University

Christine Kubiak

ECRIN

Jacques Demotes

ECRIN

Regina Demlová

Masaryk University

Emília Carreira Monteiro (✉ emilia.monteiro@nms.unl.pt)

<https://orcid.org/0000-0002-0570-0765>

Research

Keywords: investigator initiated clinical trials, funding; clinical trials registry, publication of study results

Posted Date: February 27th, 2020

DOI: <https://doi.org/10.21203/rs.2.24789/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Therapeutic Innovation & Regulatory Science on May 18th, 2021. See the published version at <https://doi.org/10.1007/s43441-021-00293-w>.

Abstract

Background: Clinical trials provide one of the highest level of evidence to support medical practice. Investigator initiated clinical trials (IICTs) answer relevant questions in clinical practice that may not be addressed by industry. This study aims to compare, for the first time, two European Countries in terms of registered IICTs, respective funders, scientific outcome and its impact on the national performance in IICTs.

Methods: A retrospective systematic search of registered IICTs, over the past 13 years, using four clinical trials registries was carried out in two European countries with similar population and Gross Domestic Product (GDP) but with different governmental models to fund clinical research. Each completed IICT was screened for sponsors, funders, type of intervention and associated publications.

Results: IICTs involving Czech Republic and Portugal were n=439 (42 % with hospitals as sponsors) and n=328 (47 % with universities as sponsors), respectively. Funding agencies (national and international) supported only 25 % and 18 % of the IICTs in Czech Republic and Portugal, respectively. The Czech Ministry of Health, through the Health Research Council, supported 61 IICTs and the Portuguese Ministry of Science, Technology and High Education, through Fundação para a Ciência e Tecnologia , supported 27 IICTs. Among these, trials with investigational medicinal products represent 52 % (n= 32/61) and 4 % (n=1/27) in Czech Republic and Portugal, respectively. The Czech Republic presented a higher percentage of IICTs' publications in high impact factor journals (IF>21) with national investigators as authors, when compared to Portugal (86 % vs 15 %).

Conclusion: We found a better performance of Czech Republic in terms of number and scientific outcome of IICTs when compared to Portugal. These findings might be related to the existence of specific and periodic funding for clinical research in Czech Republic, although further data still need to be collected to confirm this relationship.

Background

In the last decades, clinical research played a crucial role on increasing the medical knowledge for the prevention, diagnostic, treatment and cure of diseases. Clinical trials provide one of the highest level of evidence to support medical practice. Investigator-initiated clinical trials (IICTs) are pivotal to generate relevant and unbiased data decisive for the implementation of new therapies and better-informed decisions by health regulators [1]. However, the importance and relevance of IICTs rely heavily on its independence and impartiality, which in turn is directly linked to the funding source. Some IICTs are funded by industry, which can introduce a bias in the outcome of these studies. In fact, a systematic review of 1140 studies demonstrated that industry-sponsored clinical trials were significantly more likely to reach conclusions favourable to the sponsors than those who were not industry-sponsored trials [2].

Therefore, public national funding agencies have a critical role on supporting fully independent clinical research with the sole purpose of benefiting the large patients' population through the improvement of

medical knowledge. Public funding of IICTs can also play an important role on addressing important clinical questions that remain unresolved because they are not addressed in industry-funded trials. Crowe and colleagues showed that there is an important mismatch on clinical research priorities identified by the patients and the clinicians, which in part is affected by the commercial aspect of clinical research [3].

The unbalanced ratio between private and public funding of IICTs (and its impact on national health systems through the definition of public policies for the treatment of diseases) is particularly relevant in countries with negligible expenditure in this area, which is usually associated to limited funds for the promotion of clinical research. It is important to generate significant scientific data in order to be able to provide better and informed guidance for the funding of IICTs by the national public funding agencies.

Czech Republic and Portugal have similar population numbers (10.6 million and 10.3 million, respectively) as well as GDP per capita (€14.8 thousand and €16.9 thousand, respectively), which makes them comparable countries for such study. Both countries are members of the European Union and thus have access to the same funding schemes and also operating under to the same health regulatory environment (supervised by the European Medicines Agency). Additionally, both countries are members of the European Clinical Research Infrastructure Network (ECRIN-ERIC), which is a public, non-profit organisation committed in supporting and facilitating multinational independent clinical trials in Europe.

Currently, the Czech Clinical Research Infrastructure Network (CZECRIN) aims its activities in order to bring together academic research institutes, scientists and policymakers in discussion on issues related, particularly public funding of the clinical research in Czech Republic. CZECRIN's specific goal is to promote and support academic research on the national basis and the integration of national investigators in multinational clinical studies.

The Portuguese Clinical Research Infrastructure Network (PtCRIN) has been developing several national studies where the status of IICTs in Portugal were assessed [4,5]. Despite the relevance of such data to define national strategies for this area, the impact of such analysis can be maximised through a comprehensive benchmarking with other European countries, particularly the ones with similar characteristics. Therefore, intending to perform a comprehensive assessment of the current situation, this study analysed the type of registered IICTs in Czech Republic and in Portugal and for the first time unveiled the differences in terms of funding policies and scientific outcome.

Methods

We identified past or current IICTs registered and starting in two European countries (Czech Republic and Portugal) from 01/01/2004 to 31/12/2017 to identify detailed studies' characteristics such as the funding sources and the respective scientific impact. For that we performed a search in four clinical trial registries (CTRs): ClinicalTrials.gov, European Clinical Trials Registry (EU-CTR), International Standard Randomised Controlled Trial Number (ISRCTN) registry, and the Australian New Zealand Clinical Trials Registry (ANZCTR) by selecting trials registered and with recruitment sites in Czech Republic or Portugal.

These CTR encompass 81% of the registrations uploaded to the International Clinical Trials Registry Platform (ICTRP) from WHO, according to the information provided by others [6]

Furthermore we collected and compared the national public policies implemented by the Portuguese and Czech governments to promote clinical research during this timeframe.

Search methodology for clinical trials identification in each database

Step 1. The search in the EU-CTR allowed to include as general term “non-commercial” therefore eliminating the commercial studies. The timeframe selected was from 01/01/2004 until 31/12/2017 as well as the countries, Czech Republic or Portugal. No other requirement in the advanced search field was selected.

Step 2. As the discrimination between commercial and non-commercial clinical trial is not possible at the ClinicalTrials.gov platform, an advanced search was performed. The ICTs were extracted by selecting the predefined options: “Interventional studies”, the above-mentioned time period, each one of the countries, restricting to: NIH (U.S. National Institutes of Health), Other U.S. Federal agency, all others (individuals, universities, organizations) and Industry were chosen.

Step 3. Registrations in the BiomedCentral CTR are associated with ISRCTN. In this CTR it was not possible to refine the search with the exception of selecting Czech Republic or Portugal as the recruiting country. Trials initiated before or after the referred timeframe were discarded.

Step 4. In the ANZCTR, we performed the search in the selected timeframe, using Czech Republic or Portugal as the recruiting country. Registrations in this CTR have the initial code ACTRN.

In steps 1-4 some studies were discarded, using as exclusion criteria: industry sponsored trials; starting date before 01/01/2004; sponsor or recruitment site not involving Czech Republic or Portugal; non-intervention trials. The search results were reviewed individually by two independent experts in each national team to confirm the compliance with the inclusion and exclusion criteria.

Data extraction, duplicates and complementary information

Step 5. Information about trial identification (Trial ID) number (main and secondary), recruitment status, sponsor name and country, trial title, trial phase (when applicable), type of intervention, therapeutic area, design characteristics, type of funding and publications of the completed studies, were extracted manually and independently from the registered records (from 1/03/2018 to 31/08/2018), gathered and organized in Excel sheets. Forty percent of the records were double-checked by two individuals from each team and discussed until a consensus was reached.

Step 6. Duplicates were identified in each database, when secondary IDs were provided or when the sponsor and the study title were the same. The same study registered in different CTRs was considered duplicated and removed at this point of the search. When complementary information was provided in

different registrations about the same study it was added to the respective entry in the working Excel sheet. None of the studies identified had recruitment sites in both countries, so no clinical trial is considered in both databases.

Sponsors were coded as: Disease-Specific Organization (Disease associations or research institutes dedicated to a specific therapeutic area), Foundation, Hospital, Research Institutes (non-specific therapeutic area), University, and others (Private health clinic, Funder Agency, acting as sponsor). In the four CTRs, the funding source was identified in different fields. Both in ISRCTN and ANZCTR there is a specific field entitled "Funder". In Clinicaltrials.gov CTR the funders was identified from the field "Sponsor and Collaborators". In EU-CTR the funder was identified in the field "sources of monetary support". All the funders identified in these CTRs were classified as: i) Public organizations (non-profit organization such as public institutions, funding agencies, disease specific organizations); ii) Private organization (for-profit organization - Industry); iii) Both, when the funding is provided by the industry and one or more public organizations; iv) Not Indicated, when the information was not provided in any registry or in the publication.

When only the sponsor was mentioned in the ClinicalTrials.gov registry, we considered it as the funder. The support of funding agencies was perceived through secondary IDs where the code of the grant agreement is in some cases added. Exclusive funding for PhD or Post-Doctoral grants was not considered.

Search of publications of completed IICTs

Step 7. Information regarding the publications of the registered and completed IICTs were manually and independently screened. The Trial ID was used to search abstracts of journals indexed in Medline (using PubMed) as well as in the four CTRs. By the principal investigator's name was possible to identify publications, when no paper was found with the previous strategies. In some publications, the Trial ID was not included in the abstract, which rendered the search more difficult. All completed trials and published until 31/12/2017 were considered for further analysis. Subsequently, screening of each publication was performed to complete the information about the funding sources of IICTs to identify any other relevant information that was not complete in CTRs. The journal's impact factor was obtained from Web of Science, Research Gate or Bioxbio.com, considering this order when different impact factors for the year of publication were found for the same journal. Around 40% of the data were mutually exchanged between Czech and Portuguese team and double checked by two independent reviewers.

Results

A total of 3496 and 1427 registrations were found in the four CTRs involving Czech Republic and Portuguese institutions, respectively: ClinicalTrials.gov, EU-CTR, ISRCTN, and ANZCTR. Clinical trials were screened to isolate those with a non-commercial sponsor, recruiting sites in Czech Republic or Portugal, and a start date between 01/01/2004 and 31/12/2017.

Identification of non-commercial studies

The number of trials identified in each database is shown in Figure 1. After discarding industry-sponsored trials, non-interventional studies, or those with no recruiting sites in Czech Republic or Portugal, 485 and 378 non-commercial trials (i.e. IICTs) were respectively considered eligible from all the screened databases. The same trial registered in different CTRs was separated and considered as duplicate. After discarding duplicates, a total number number of 439 IICTs were identified involving Czech Republic whereas for Portugal 328 trials were found. Forty-one percent and 49% of the studies were already completed and from those 41% and 58% were published, in Czech Republic and Portugal, respectively.

Characteristics of IICTs in Czech Republic and in Portugal

In both countries, most of IICTs has a national sponsor and were performed in the respective country (Figure 2A) with a low percentage of multinational trials (implemented in other countries) – 6% in Czech Republic (n=15/242) and 4% in Portugal (n=8/185). Both countries have also the same percentage of trials with international sponsors (41%) (Figure 2A). In Czech Republic, most trials' sponsors (42%; n=183/439) were hospitals while in Portugal, universities assume the sponsorship in higher number of trials when compared to the other types of organizations (47%; n=153/328) (Figure 2B).

IICTs in both countries are mainly funded by public organizations (Figure 2D) such as universities, hospitals, disease specific organizations, foundations and funding agencies: 78% (n=343/439) in Czech Republic and 69% (n=226/328) in Portugal. Considering all types of interventions funded by public organizations, 50% (n=173/343) are trials with IMPs in Czech Republic and only 27% (n=60/226) in Portugal. In the latter, most trials funded by public organizations, 36% (n=82/226), are behavior-based (Figure 2 D, 2E). Details about each registry are provided as Supplementary Information 2 (S.I.2).

Clinical trials funded by national and international funding agencies

One of the great public funders of the IICTs in both countries were funding agencies (national and international) corresponding to 29% (n=109/381) in Czech Republic and 21% (n=60/282) in Portugal of the public funding. The total number of trials indicated above (381 and 282) refers to those funded by public organizations alone or together with private institutions (Figure 2D: Public and Both). From the 109 IICTS trials funded by governmental agencies in Czech Republic 65 % (n=71) of the trials were funded by national funding grant agencies while the remaining 35 % (n=38) IICTs were funded by international counterparts (Figure 3A). Figure 3A shows that both national and international agencies mainly fund trials with IMPs. Among the 61 trials funded by the Czech Health Research Council (Table 1), 32 (52%) are testing medicinal products (data not shown).

On the other hand, among the 60 IICTs in Portugal receiving financial support from funding grant agencies, only half of these (n=30/60) were funded by national funding grant agencies or funding programs (Figure 3B) while the other half was funded by international funding agencies. Among the 27

trials funded by *Fundação para a Ciência e Tecnologia* (Table 1) only one (4%) is testing medicinal products (data not shown).

Table 1 - National and International funding agencies and programs in Czech Republic in and Portugal and respective number of funded trials. (N^o=number of clinical trials funded by the respective funding organization/program)

Czech Republic	
	N ^o of Trials
<i>National Funding Agencies / Funding Programs</i>	
Internal Grant Agency of the Czech Ministry of Health (IGA until 2014) Currently AZV (Czech Health Research Council)	61
Charles University Research Fund	10
<i>International Funding Agencies</i>	
European Commission (includes H2020 and Erasmus Program)	18
Canadian Institutes of Health Research (Canada)	7
European Regional Development Fund	6
Medical Research Council (UK)	7
Portugal	
<i>National Funding Agency/ Funding Programs</i>	
	N ^o of trials
<i>Fundação para a Ciência e Tecnologia</i> (FCT)	27
National Structural funding (COMPETE, PRODEP)	2
ARDITI - <i>Agência Regional para o Desenvolvimento da Investigação</i>	1
<i>International Funding Agencies</i>	
European Commission (includes H2020 and IMI Programs)	17
Australian National Health Service and Medical Research Council	5
National Institutes of Health (NIH, USA)	3
British Medical Research Council (UK)	2
EEA Grants	1
Carlos III Institute of Health (Spain)	2

The level of participation of these two countries in international grants was similar (n=38 and n=30, respectively), most of these involving trials with IMPs in both cases (Figure 3A, 3B).

The organizations receiving national funds, thus acting as sponsor, in higher number of trials in Czech Republic were hospitals (32%: n=35/109) and universities (22%: n=24/109). Whereas in Portugal were the universities (40 %: n=24/60) that sponsored more trials funded by national funding agencies followed by hospitals (7 %: n=4/60). Portuguese hospitals sponsored more trials funded by international funding grants than with national funding grant agencies (n=8 vs n=4).

Table 1 shows all the funding grant agencies identified both in the registries and in the publications for each completed and published clinical trial. In Czech Republic there were a higher number of trials funded by national funding agencies and the number of registrations is gradually growing every year since 2004 (S.I.1, Fig. 1 D,E). When compared to Czech Republic, a lower number of funded IICTs by public funding

agencies were identified in Portugal, however, the national investigators have been involved in trials with more diverse funding opportunities, especially international ones.

National policies for clinical research

Both countries present national public policies implemented (or not) for clinical research, in particularly IICTs, which are summarized in Table 2. The data were collected from national legal decisions, analysis of the call's eligibility criteria for funding national infrastructures and projects as well as higher education institutions in each country.

There have been legal decisions to establish clinical research as a priority that included the membership of ECRIN-ERIC and the definition of the clinical investigator status in both countries [7-13]. The Internal Grant Agency (IGA) of the Ministry of Health supporting medical research and development was established in 1990 in Czech Republic and has been replaced by Czech health research council, AZV, founded on 01/04/2014 [17,18]. This council, launch calls each year and supports the selected applications of clinical research in the different medicine areas. The establishing the AZV and defining the national priorities of oriented research, experimental development and innovations are the long-term strategies of the Czech government to support the clinical research in medicine. Nevertheless, to our best knowledge in Czech Republic, the higher education courses specific to train clinical trials professionals are being prepared. In Portugal, the national government supported and invested in specific training for medical doctors¹⁴ and research team professionals from hospitals [14].

Table 2 – National public policies implemented by the Portuguese and Czech governments to promote clinical research.

Public Policies	Czech Republic	Portugal
Establish clinical research as a priority	Yes [7]	Yes [8,9,10]
Be member of ECRIN-ERIC	Yes [11]	Yes [12]
Define a legal specific status for clinical investigators	Yes [13]	Yes [8]
Invest in public infrastructures to promote/support IICTs	Yes	No
Specific and periodic funding for IICT	Yes	No
National funding agency specific for health research	Yes	No*
National public initiatives for clinical research team's capacitation	No**	Yes [14,15]

ECRIN- ERIC: European Clinical Research Infrastructure Network - European Research Infrastructure Consortium

*A national agency (AICIB) for clinical research funding is now being implemented in Portugal [16];

** A course dedicated to clinical trials management is under preparation

Clinical trials published in peer-reviewed scientific journals

In Czech Republic, there are 41% of published trials among the 180 completed while in Portugal, from the 144 completed trials, 55% are published in peer-reviewed journals (Figure 1, step 7). In Czech Republic, a higher percentage of published studies focus on IMPs (44%, n=32/73), followed by surgery and procedures (32%). On the other hand, in Portugal, most publications focus on behavior studies (37%, n=29/79) followed by IMPs (32%) (Figure 4 A).

The impact factor (IF) of the journal where these IICTs were published varies widely between 0 to 72. Thirty percent (30%, n=23/73) of the trials performed in Czech Republic with publications were published in journals with IF between 6 to 20. Around 75% (n=59/79) of published papers with trials involving Portuguese organizations, have an IF below 5 and only 16% (n=13/79) were published in journals with IF above 20. The average IF of all these journals is similar for both countries and is around 9. Portuguese investigators are authors/ co-authors of 15% of the papers published in journals with IF>20, conversely to what is observed with Czech investigators who authored/co-authored of 86% of the papers published in high impact factor journals (Inset B1, Figure 4B). Furthermore, international funding agencies funded 71 % of trials in Czech Republic and only 31% in Portugal that were published in journals with IF>21 (Inset B1, Figure 4B). None of these published trials in high impact journals was funded by the Portuguese national funding agency while in Czech Republic, one of these trials was funded by the national funding agency. Around half of the trials published in journals with IF>21 are funded by private funders (43% for Czech Republic and 54% for Portugal). Additionally, most of these published trials were multinational and focused in IMPs, in both countries.

Discussion

In this study, a systematic search of IICTs registered in four CTRs was conducted with the main goal of comparing the type of studies, main funders and scientific output in Czech Republic and in Portugal. The methodology used in this work, allowed us for the first time to have a picture of IICTs in two European countries with similar GDP and population, collecting information both from CTRs and publications.

Globally we found a better performance of Czech Republic in terms of higher number of IICTs, including those with IMPs, the publication with a higher scientific impact and with more national authorships, when compared with Portugal. These findings suggest that a funding agency more focused in clinical research as the Czech Republic funding agency, may be associated with a high national performance

The majority of IICTs in Czech Republic and in Portugal were sponsored by national organizations (Figure 2A). Only a small percentage of the national organizations were sponsoring multinational IICTs (3,1% in Czech Republic and 2,4% in Portugal), in line with previous reports, where only 3% of all IICTs in the International Clinical Trials Registry Platform (ICTRP) are international [19]. In Czech Republic sponsors are mainly hospitals while in Portugal are the universities (Figure 2B). The Czech health research council funds clinical research only if a national hospital is the sponsor. International organizations are not eligible by AZV and FCT meaning that multinational trials require international instruments (e.g Era-Net and Co-funding).

In this study we show that the main funders of IICTs in both countries are public or non-profit organizations (Figure 2D). However, we cannot provide accurate data on the origin of funding because, as we previously published, CTRs do not provide a clear separation between sponsor and funders⁵. Only a small percentage of the public funding to IICTs in both countries is provided by national funding agencies (25% in Czech Republic and 18% in Portugal – Figure 3). In Portugal, national funding agency is mainly used to provide financial support to behavior studies (Figure 3B) that are less challenging in terms of costs, regulations, guidelines compliance and impact when compared to clinical trials with IMPs. Only 1 of the 27 studies supported by FCT is testing medicinal products (4%). In contrast, international funding agencies mainly fund trials with IMPs in Portugal (Figure 3B). This difference was not found in Czech Republic where trials with IMPs were funded by both national and international funding grant agencies (Figure 3 A). The health funding agency in Czech Republic (AZV) funded 32 studies testing medicinal products out of 61 (52%). We may attribute these findings to the fact that AZV launch calls more frequently and adequate to support trials with IMPs. During the time period studied in the present work FCT launched only one call, in 2007, specifically focused in clinical research. The Portuguese Ministry of Health had a financial contribution to this call and a total amount of 9 M € were used to fund 63 projects [20]. However, none of these funded studies were found in our search, probably because most of them were not interventional studies or interventional without IMPs which registration is desirable but not mandatory. Nevertheless, screening the information provided by FCT we found at least one interventional study with IMP that was not properly classified, consequently not registered in a database by the investigators [21].

In Czech Republic, University hospitals are pressured to apply to grant support and carry out clinical research, because most physicians working in the hospital are university employees at the same time and need to build up their career as researchers. Moreover, there is a lack of experienced grant offices in Czech Republic which would help the investigators to prepare an application for international grant call, e.g. H2020, IMI2. Additionally, the Czech health research council funds clinical research only if a national hospital is the sponsor and grant funding is used in the country. However, the mandatory insurance to initiate a clinical trial with medicines is not eligible in these grants' call which might hamper the initiation of more trials.

In theory, the majority of Hospitals in Portugal have an office dedicated to support clinical research (as a government decision from 2015) [9] – but only a few can support physicians in the design or implementation of more complex clinical trials involving IMPs or medical devices, or even provide support to prepare proposals for national or international funding. The concept of academic clinical trial units (CTU) introduced in these two countries by ECRIN has been detrimental to support clinical investigators and multinational IICTs [22], in the implementation of IICTs, especially in IMPs and/or medical devices trials (due to a more complex regulation), during all phases of the process (from the idea until the close out). Universities and biomedical research institutes in Portugal detected earlier the need of professional supporting offices to prepare and manage national and international research projects. In an attempt to share knowledge and resources in 2016 a Portuguese government decision created the concept of

Clinical Academic Centres (CAC) – joining hospitals, universities and research institutes around a medical school [10]. Currently, 9 CACs are officially established in Portugal, however they are still deciding on the respective organizational strategy. In line with what is established in Czech Republic since 2004, in Portugal a new agency to fund exclusively clinical research studies: *Agência para a Investigação Clínica e Investigação Biomédica* (AICIB), focusing on translational medicine products trials, was launched in 2018 but is not yet operational [16].

The existence of national funding grant agencies is of major relevance to implement pilot IICTs that later could be escalated to the European level. Submission of a project proposal that include a multinational trial to a international funding grant agency that had already a national pilot might have a higher probability to get financial support. Moreover, the national funding schemes would also contribute to empower investigators to internationalize their ideas and coordinate multinational collaboration consortiums to capture international funding.

The national governments and European Commission investment in clinical research infrastructures have been critical for the development of this area [23,24]. Both, Czech Republic and Portugal governments have been investing in European infrastructures of clinical research such as ECRIN-ERIC. However, while in Czech Republic the government also invested in the national network of CTUs, in Portugal the investment was limited to the ECRIN-ERIC membership fee. Recently a positive discrimination for clinical research has been introduced in the Portuguese infrastructures roadmap national strategy [25]. Germany, France, and the UK are good examples to show the increase in the number of IICTs after the investment of respective governments in both the funding of IICTs and support infrastructures⁴.

The investment of the Portuguese government, public and private universities in post-graduation courses, including the Portugal Clinical Scholars Research Training (PTCSRT) [15] and the Clinical Investigator Certificate, CLIC [14] is an asset to trigger a high quality clinical investigation. However, strategies to allocate research time to clinical investigators still need to be implemented [8].

The publication that resulted from the IICTs with authorship of the national investigator as well the respective journals impact factor might reflect the impact of the investment of national governments in clinical research. According to our results Czech Republic has had a better return of the investment in this field, achieving a higher number of publications in journals with IF above 6 compared with Portugal and 71% of the publication were funded by national funding agencies. When compared to Czech Republic, Portugal has slightly a higher number of published completed trials and a higher number of publications in journals with IF greater than 21 (n=13 vs n=8), however these participation of Portuguese recruiting site does not translate in more authorships of Portuguese investigators in the publication since only 15% of these have Portuguese authors, whereas 86% of publications with the involvement of Czech Republic recruiting sites have national investigators as authors (Figure 4B). The values above mentioned might be underestimated because in this work, only studies registered in CTR and the first publication with results of each completed IICTs were considered.

In this study, we observed a low number of multinational IICTs registered in both countries when compared to other countries [6]. This difference might be due to the specific rules of each national agency regarding the eligible cost. If only considered national eligible cost, this impose several limitations in case of multinational clinical trials. It would be worth following the example of countries like Denmark (Innovation Fund Denmark) [26] or the UK [27] who establish new rules to support the funding of multinational clinical trials by their national grant agencies.

Furthermore, the relevance and impact of IICTs for the continuous improvement of therapies and the development of new public policies rely on the results' independence from the interests of any other stakeholders [28]. Therefore, it is critical for the states to promote IICTs through a comprehensive and stimulating set of public policies and funding. For example, Italian government decided to invest on IICTs funding, through the Italian Medicines Agency (AIFA) that resulted in an increase of the number of independent clinical research and scientific outputs [29,30]. This initiative started in 2005 and an amount of 40M€/year have been provided by the industry to AIFA, to fund competitive IICTs projects developed by Italian physicians working in the public/non-profit sector [30].

As a limitation of this study, the number of IICTs with IMPs in both countries might be underestimated due to lack of registration and/or misclassification, although being mandatory [31,32]. Similar underestimation might also have occurred in the registration of the other type of interventional studies since these are not mandatory in both countries. Nevertheless, with this work, we expect to reinforce the need of registration of all types of clinical studies, in particularly those funded by national funding agencies. This would facilitate the tracking of the studies in which a huge investment was made, as well as the assessment of the outcomes in terms of publications, guidelines, etc.

In our view, the development of clinical research relies in a national strategy that gather health authorities with science, innovation and economy stakeholders. A change in the way health care units value clinical research outcomes and how their performance is evaluated and rewarded, requires a new paradigm. The implementation of clinical academic centers [10] might be a useful strategy to move forward.

Conclusion

For the first time, two European Countries were compared in terms of the performance related to IICTs and the respective scientific outcome. Our results showed a better performance of Czech Republic in terms of number and scientific outcome of IICTs when compared to Portugal. These findings might be related to the existence of specific and periodic funding for clinical research in Czech Republic, although the factors behind this difference are difficult to unravel with the methodological approach in this study. We anticipate using the results of this study as a baseline to the better appraisal of IICTs evolution in the upcoming years and inspire other countries to do the same type of evaluation.

Abbreviations

AICIB	Agência para a Investigação Clínica e Investigação Biomédica
AIFA	Italian Medicines Agency
ANZCTR	Australian New Zealand Clinical Trials Registry
AZV	Czech health research council
CAC	Clinical Academic Centers
CLIC	Clinical Investigator Certificate
CTR	Clinical Trial Registry
CzeCRIN	Czech Clinical Research Infrastructure Network
ECRIN-ERIC	European Clinical Research Infrastructure Network-European Research Infrastructure Consortium
EU-CTR	European Clinical Trials Registry
FCT	Fundação para a Ciência e Tecnologia
GDP	Gross Domestic Product
IICTs	Investigator Initiated Clinical Trials
IMP	Investigational Medicinal Product
ISRCTN	International Standard Randomised Controlled Trial Number
NIH	U.S. National Institutes of Health
PtCRIN	Portuguese Clinical Research Infrastructure Network
PTCSRT	Portugal Clinical Scholars Research Training (

Declarations

Ethics approval and consent to participate

Not applicable. The data used in this work was obtained from public clinical trials databases.

Consent for publication

Not applicable. The data used in this work was obtained from public clinical trials databases.

Acknowledgments

The Portuguese team thank to José Paulo Esperança and Ana Quartin from *Fundação para a Ciência e Tecnologia* (FCT) for providing information on call funding with Ministry of Health (PIC/IC/2007).

Funding

In Czech Republic, this work was supported by the European Regional Development Fund - Project CZECRIN_4 PACIENTY (No. CZ.02.1.01/0.0/0.0/16_013/0001826) and Large Research infrastructure CZECRIN – LM2015090.

CM and FS were supported by Fundação para a Ciência e a Tecnologia (FCT, through the membership fees to ECRIN-ERIC published at Portaria nº 237/2014).

The funders did not interfere with the design of the study, collection, analysis and interpretation of data as well as with the writing of the manuscript.

Authors' contributions

ECM, CM and LH conceived and designed the study. CM and LH, contributed equally to this work and carried out the search of the registrations and publications independently. Both CM and LH double checked 40% of the information gathered in the registrations and publications. All authors analysed and interpreted data, drafted and performed a critical review of the manuscript. All authors have approved the submitted version of the manuscript.

Availability of data and materials

All data generated or analysed during this study are included in this published article [and its supplementary information files].

Competing interests

The authors declare that they have no competing interests

References

1. Konwar M, Bose D, Gogtay NJ, Thatte UM. Investigator-initiated studies: Challenges and Solutions. *Perspect Clin Res.* 2018; 9:4 p. 179-183. Doi: 4103/picr.PICR_106_18
2. Bekelman JE, Li Y, Gross, CP. Scope and Impact of Financial Conflicts of Interest in Biomedical Research – A Systematic Review. *JAMA.* 2003; 289:4 p. 454-465. Doi:10.1001/jama.289.4.454
3. Crowe S, Fenton M, Hall M, Cowan K, Chalmers I. Patients', clinicians' and the research communities' priorities for treatment research: there is an important mismatch. *Res. Involvement and Engagement.* 2015; 1:2. Doi: 10.1186/s40900-015-0003-x
4. Madeira C, Pais A, Kubiak C, Demotes J, Monteiro EC. Investigator-initiated clinical trials conducted by the Portuguese Clinical Research Infrastructure Network (PtCRIN). *Contemporary Clinical Trials Com.* 2016; 4 p. 141-148. Doi.org/10.1016/j.conctc.2016.08.002
5. Madeira C, Santos F, Kubiak C, Demotes J, Monteiro EC. Transparency and accuracy in funding investigator initiated clinical trials: a systematic search in clinical trials databases. *BMJ Open.* 2019; 9, e023394. Doi:10.1136/ bmjopen-2018-023394

6. Zarin DA, Tse T, Williams RJ, Rajakannan T. Update on Trial Registration 11 Years after the ICMJE Policy Was Established. *NEJM*. 2017; 376:4 p. 383-391. Doi: 10.1056/NEJMSr1601330
7. Roadmap for Large Research, Development and Innovation Infrastructures in the Czech Republic - Update 2011 Retrieved from https://www.vyzkumne-infrastruktury.cz/wp-content/uploads/2019/06/Cestovni-mapa-velkych-vyzkumnych-infrastruktur-CR_2011_EN.pdf. Accessed July 2019
8. Resolução do Conselho de Ministros (RCM) n.º 18/2015, Diário da República, 1.ª série – N.º 67 – 7 de abril de 2015. <https://dre.pt/web/guest/pesquisa/-/search/66902772/details/maximized>. Accessed September 2019
9. Despacho n.º 7216/2015, Diário da República, 2.ª série – N.º 126 – 1 de julho de 2015. <https://dre.pt/home/-/dre/67644371/details/maximized> Accessed October 2019.
10. Portaria n.º 237/2014, Gabinetes do Secretário de Estado Adjunto e do Orçamento e da Secretária de Estado da Ciência - Diário da República, 2.ª série – N.º 60 – 26 de março de 2014. <https://www.acm.gov.pt/documents/10181/43818/Aviso+n.%C2%BA+4107-2014.pdf/aa89bcc8-4e1a-4110-a92d-0a8f9eb6b182>. Accessed September 2019
11. Decision Ref. No. :MSMT-3495/2014
12. Portaria n.º 237/2014, Gabinetes do Secretário de Estado Adjunto e do Orçamento e da Secretária de Estado da Ciência - Diário da República, 2.ª série – N.º 60 – 26 de março de 2014. <https://www.acm.gov.pt/documents/10181/43818/Aviso+n.%C2%BA+4107-2014.pdf/aa89bcc8-4e1a-4110-a92d-0a8f9eb6b182>. Accessed September 2019
13. No. 378/2007 Coll., Decree No. 226/2008 Coll.
14. Clinical Investigator Certificate, <http://clic.pharmaceutical-medicine.pt/> . Accessed October 2019
15. Portugal Clinical Scholars Research Training, <https://postgraduateeducation.hms.harvard.edu/certificate-programs/custom-programs/portugal-clinical-scholars-research-training> Assessed October 2019
16. Resolução do Conselho de Ministros (RCM) n.º 20/2016, Diário da República, 1.ª série – N.º 70 – 11 de abril de 2016. Retrieved from <https://data.dre.pt/eli/resolconsmin/20/2016/04/11/p/dre/pt/html>. Accessed September 2019
17. Czech Health Research Council (AZV), <http://www.azvcr.cz/en>, Assessed October 2019
18. Czech publication by AZV Director about the establishment of the Czech Health Research Council, <https://www.tribune.cz/clanek/40308-agentura-pro-zdravotnický-výzkum-česke-republiky>, Assessed October 2019
19. Atal I, Trinquart L, Porcher R, Ravaud P. Differential Globalization of Industry- and Non Industry– Sponsored Clinical Trials. *PLoS ONE*. 2015; 10:12, e0145122. Doi:10.1371/journal.pone.0145122
20. Fundação para a ciência e Tecnologia, Concurso de Projectos de I&D em Investigação Clínica <https://www.fct.pt/apoios/projectos/concursos/invclinica/> Accessed October 2019

21. Almeida N, Romãozinho JM, Donato MM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Sofia C. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for *Helicobacter pylori* eradication: a proof-of-concept study. *Helicobacter*. 2014; 19:2 p. 90-7. Doi: 10.1111/hel.12106.
22. European Clinical Research Infrastructure Network (ECRIN), <https://www.ecri.org/activities/trial-management> Assessed October 2019
23. von Niederhäusern B, Magnin A, Pauli-Magnus C, The impact of clinical trial units on the value of clinical research in Switzerland, *Swiss Med Wkly*. 2018;148:w14615 doi:10.4414/smw.2018.14615
24. Maier-Lenz H. Academic strength in Germany, *Appl. Clin. Trials* 2011; <http://www.appliedclinicaltrials.com/academic-strength-germany>. Accessed October 2019
25. Despacho n.º 4157/2019; *Diário da República*, 2.ª série – N.º 75 – 16 de abril de 2019 ; <https://dre.pt/home/-/dre/122109185/details/maximized>, Accessed October 2019
26. Innovation Fund Denmark, <https://innovationsfonden.dk/en> Accessed October 2019
27. Fox L, Toms C, Kernaghan S, Snowdon C, Bliss JM. Conducting non-commercial international clinical trials: the ICR-CTSU experience. *Trials*. 2017; 18:440. Doi 10.1186/s13063-017-2176-0
28. Neyt M, Christiaens T, Demotes J, Walley T, Hulstaert F. Publicly funded practice-oriented clinical trials: of importance for healthcare payers. *J. Comp. Eff. Res.* 2016; 5:6. p. 551–560; DOI:10.2217/cer-2016-0018
29. Neyt M, Christiaens T, Demotes J, Hulstaert F. Publicly funded Practice-oriented Clinical Trials. *Health Services Research (HSR) Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports 2015; 246. D/2015/10.273/53.*
30. Italian Medicines Agency R, Development Working Group. Feasibility and challenges of independent research on drugs: the Italian medicines agency (AIFA) experience. *Eur J Clin Invest.* 2010; 40:1 p. 69-86. Doi: 10.1111/j.1365-2362.2009.02226.x.
31. Clinical Trials Directive 2001/20/EC, European Commission https://ec.europa.eu/health/human-use/clinical-trials/directive_pt Accessed October 2019
32. EudraCT public home page, <https://eudract.ema.europa.eu/> Accessed September 2019

Figures




Figure 1

Flowchart showing the systematic search of non-commercial clinical trials (i.e. IICTs), involving the Czech Republic and Portuguese institutions recruiting participants. The search was performed in four clinical trial registries, CTRs (EU-CTR, Clinicaltrials.gov, ISRCTN and ANZCTR). Studies starting from 01/01/2004 until 31/12/2017 were identified in each of the databases separately (Steps 1-4). After discarding commercial trials all remaining studies were gathered in one Excel sheet for each country (Step 5). Duplicate studies were also discarded, and the final number of trials was cleaned and harmonized (Step

6). Further details were collected from all the databases, including the identification of completed studies. Publications published until December 2017, with results from completed studies were identified (Step 7).




Figure 2

Characteristics of IICTs in the Czech Republic and in Portugal. Number of trials according to the sponsor (national vs international) and to the involvement of other countries in national sponsored trials (national vs multinational trial) (A); Percentage and number of trials according to the type of sponsor organization

(B) and number of trials according to the type of most frequent interventions sponsored by universities or hospitals (n= 243 out of 333 for the Czech Republic and n= 177 out of 224 for Portugal) (C); Percentage and number of trials according to the type of funder (D) and number of trials according to the type of most frequent intervention funded by public or private organizations (n= 260 out of 365 for the Czech Republic and n= 201 out of 257 for Portugal) (E).

Trials funded by funding agencies




Figure 3

Characteristics of ICTs funded by funding agencies. Number of trials funded with national or international funding agencies in the Czech Republic (A) and in Portugal (B), according to the type of intervention and sponsor.




Figure 4

ICTs published in peer-reviewed journals according to the type of intervention (A) and impact factor of the journals (B). Papers published in 2018 were not considered. Inset of B (B1): clinical trials published in journals with impact factor higher than 21.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryInformation1.docx](#)
- [EQUATORChecklist.docx](#)
- [SupplementaryInformation2.docx](#)